Scinai Immunotherapeutics Ltd. (SCNI) Financial Statements
Scinai Immunotherapeutics Ltd. (SCNI) reported trailing twelve-month revenue of $1.5M (up 29.6% year on year) and net income of -$2.6M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$7.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SCNIScinai Immunotherapeutics Ltd.Follow SCNI — free
—
Price chart with a free account
- Market cap
- 3.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 25.6 | 0.7 | 1.3 | 1.5 | |
| Gross profit | — | -0.6 | -2.7 | -3.8 | |
| Research & development | 5.2 | 5.5 | 2.4 | — | |
| Operating income | -9.7 | -8.6 | -7.5 | -8.4 | |
| Pre-tax income | -6.5 | 4.8 | -8.3 | -2.6 | |
| Net income | -6.5 | 4.8 | -8.3 | -2.6 | |
| Diluted EPS ($) | 0.00 | — | -0.00 | — | |
| Diluted shares (mn) | 1562.6 | 3225.5 | 9339.5 | — |
USD millions · SEC XBRL
Scinai Immunotherapeutics Ltd. — questions
- What is Scinai Immunotherapeutics Ltd.'s revenue?
- $1.5M over the twelve months to 2026-06-30, up 29.6% year on year, from its 10-Q and 10-K filings.
- What is Scinai Immunotherapeutics Ltd.'s net income?
- -$2.6M over the twelve months to 2026-06-30.
- What is Scinai Immunotherapeutics Ltd.'s free cash flow?
- -$7.5M over the twelve months to 2026-06-30.
Every figure on this page comes from Scinai Immunotherapeutics Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.